LAUREL HILL ADVISORY TO ACT AS INFORMATION AGENT AS BLACK PEARL COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF SELECTIS HEALTH, INC.

Black Pearl Equities commenced a tender offer for all outstanding Selectis Health shares at $5.75 per share in cash, with the offer set to expire on Aug. 10, 2026 (unless extended). The deal requires at least 70% of shares to be tendered plus regulatory approvals and other customary closing conditions; there are no financing contingencies. After the tender, Black Pearl plans to acquire remaining shares via a short-form merger without a stockholder vote.

Analysis

This is primarily a spread-capture situation, not a broad healthcare signal. In a thin OTC name, the key mechanism is whether arb capital can source enough stock to force the tender into the 70% threshold; if not, the downside is a fast re-rating toward a broken-deal price rather than a slow drift. The absence of financing contingency is supportive, but for microcaps the binding risk is execution friction, not funding.

The second-order read-through is modestly positive for subscale senior-housing/SNF operators and for buyers of illiquid healthcare assets: private capital is still willing to underwrite small platform deals where public-market access is poor. That said, this does not automatically lift the broader senior housing group; if anything, it highlights that public comp valuations remain too low for growth stories and that exit optionality may be privatization rather than multiple expansion.

Catalyst timing is tight: the next 2-4 weeks are about tender acceptance and spread compression, while the August deadline is the main event. The main falsifier is either a delayed closing or any sign the 70% condition becomes hard to reach; in that case the stock can gap down sharply because liquidity is limited and there is little strategic value outside the bid. Over 6-18 months, the only real implication is that other small healthcare names with weak public trading could attract similar sponsor interest, but that is a watch item, not a tradeable thesis yet.

Key Decisions for Investors

• Long GBCS only if the stock trades at a material discount to $5.75 and liquidity allows; treat it as a merger-arb position with an exit target at 1-2% below offer once tender mechanics are confirmed. Time horizon: days to 4 weeks.
• Do not short the sector on this alone; instead, use it as an alert for small-cap healthcare M&A. Watch SBRA, OHI, and VTR for any 13D/strategic chatter, but there is no immediate catalyst to buy or sell them here.
• If holding GBCS, hedge event risk by sizing as a special situation rather than a directional healthcare bet; trim aggressively if the spread does not tighten as the August deadline approaches.
• Set a hard stop on any non-close: if tender acceptance or regulatory steps slip past the stated window, assume the deal spread widens and reassess immediately rather than waiting for a formal termination.
• Contrarian watch item: if GBCS trades near the bid almost immediately, the market is likely correctly pricing this as a low-beta cash deal; skip the trade unless the implied annualized return still clears your special-sits hurdle.